The government and its supporters are beginning to claim 'benefits' of being outside the European Union some of which were always available to EU member states or, in other cases, are not benefits at all.

"If you will do this damn silly thing, don't do it in this damn silly way. This bill will come back to haunt this gov't, in the same way so many other mistakes, harrumphed to the rafters in this House, have."

A new EU directive is allowing member states to remove the charge for ‘supply and installation of solar panels’.

As the EU referendum grows ever closer, Lord Darzi, Elias Mossialos and colleagues seek to redress a lack of evidence on the role of the union on our health system.

NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU? Experts from ICON give us their views on the past, present and future of NICE’s standing on the world stage.

Six years after the referendum we can disentangle the evidence and judge the effects on health and care, says Richard Vize.

Fears extra expense and paperwork caused by Brexit will make Britain unattractive to global drugmakers.

BREXIT is causing “damage across the board” to UK science, including missing out on more than £1 billion in funding, campaigners have warned.

Britain must work with other countries to prevent friction on medicine rules post-Brexit to avoid being sidelined by the global drug industry, according to a report from the U.K.’s biggest pharmaceutical lobby group.

Brexit could have major implications for health and social care in England. Here we look at some of the latest developments that could have an impact.

Trade unions and regulatory experts warn that budget and staff cuts may lead to drug approval delays or the UK regulator simply rubber-stamping EMA decisions.

Preparing Brexit: How ready is the UK? is our second report examining government and business preparations for the end of the transition period, building on Preparing Brexit: The scale of the task left for UK government and business, published in July.

The most important Brexit event of the week came and went with relatively little fanfare, yet it marks a significant moment.

As of December 2022, UK companies importing medicines from the EU may need to set up new batch testing facilities. What will this mean for the industry and how did the situation come about?

Everyone is fishing in the same pond. Stocks built up in readiness for Brexit are having to be replenished. If another pandemic strikes, we’ll hardly be in the best position to get through it.

This note summarises the evidence so far of the impacts on Brexit on Scotland. It sets out early evidence related to areas such as trade, the workforce and EU programmes.

The negotiations which will set our relationship with our closest neighbours for the next generation are being rushed in a reckless game of chicken.

US, European, Japanese and Chinese patients could get novel medicines ahead of patients in the UK after Brexit, the CEO of French pharma Ipsen has said in an interview.

In the political realm, no one knows how Brexit’s long-running theater of the absurd will end. But for much of the business world, Britain’s departure from the European Union has effectively happened.

Criminals selling counterfeit drugs prey on the vulnerable. The threat of no deal may make anxious patients turn to them.

With fears over manufacturing costs and future investment, here’s what firms are doing.

The headlong rush to an end nobody voted for, and why No Deal is a man-made asteroid strike. ... Linguistic programming as Johnson drills the buzzphrase “undemocratic backstop” into the national mind. ... Ingrid – our secret agent within the Tory Party – finally succumbs to Stockholm Syndrome. The Government’s snappy 1,400 page No Deal for small businesses.